Detalhe da pesquisa
1.
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.
Mol Cell
; 81(10): 2183-2200.e13, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019788
2.
Human myeloma cell- and plasma-derived extracellular vesicles contribute to functional regulation of stromal cells.
Proteomics
; 21(13-14): e2000119, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33580572
3.
Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.
Br J Haematol
; 193(1): 160-170, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32945549
4.
Brick plots: an intuitive platform for visualizing multiparametric immunophenotyped cell clusters.
BMC Bioinformatics
; 21(1): 145, 2020 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32293253
5.
Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients.
Haematologica
; 109(3): 974-978, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37767561
6.
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.
Blood
; 128(14): 1834-1844, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27465916
7.
Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma.
Int J Mol Sci
; 19(7)2018 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29937522
8.
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Haematologica
; 107(1): 321-325, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34587718
9.
MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
Br J Haematol
; 169(3): 333-43, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25653020
10.
Changes in immune cell populations following KappaMab, lenalidomide and low-dose dexamethasone treatment in multiple myeloma.
Clin Transl Immunology
; 12(12): e1478, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38034081
11.
Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment.
J Clin Med
; 11(23)2022 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36498469
12.
Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with ß-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo.
Cancers (Basel)
; 14(3)2022 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35159107
13.
CYT997 causes apoptosis in human multiple myeloma.
Invest New Drugs
; 29(2): 232-8, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19907921
14.
Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma.
Front Oncol
; 11: 718502, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34513695
15.
Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma.
Methods Mol Biol
; 2261: 151-191, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33420989
16.
The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma.
Cells
; 10(12)2021 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34943972
17.
TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Leuk Lymphoma
; 62(2): 337-347, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33131357
18.
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).
Leuk Lymphoma
; 62(12): 2981-2991, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34263697
19.
Deactylase inhibition in myeloproliferative neoplasms.
Invest New Drugs
; 28 Suppl 1: S50-7, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21127942
20.
A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia.
Haematologica
; 100(2): e60-2, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25381133